Resources
Home
/
Resources
-
Integration of Mass Spectrometry into ADC Release and Stability Method Development and Process-to-Product Characterization
Valliere-Douglass John, Pfizer, Inc., 2024 -
Radical Protein Footprinting in Stabilized Whole Blood
Sharp Joshua, University of Mississippi, 2024
-
Mother, Scientist, and Small Town Dreamer: My Path Into Pharma
Peterson Penny, Tolmar, Inc., 2024
-
USP Standards and Tools to Establish System Readiness and Facilitate Implementation of the Multi-Attribute Method
Mugabe Sheila, US Pharmacopeia, 2024
-
Intact Mass Characterization of Multi-specific Therapeutic Antibodies
Mix Kalie, Sanofi, 2024
-
Development of Novel Chromatographic and Mass Spectrometric Techniques for Characterizations of BsAbs and ADCs
Ma Fengfei, Merck & Co., Inc., 2024
-
Characterization of ADCs in Serum and Formulation Buffer
Liu Tun, Johnson & Johnson, 2024
-
Middle-Down Approach Using Proton Transfer Charge Reduction Enables Unambiguous Drug-Payload Localization in Cys-Linked Antibody Drug Conjugates
Lieu Linda, University of Oklahoma, 2024
-
AutoFox® Protein Footprinting System Provides Amino Acid Resolution for Protein HOS Studies
Chea Emily, GenNext Technologies, Inc., 2024
-
Immunocapture Based LC/MS Investigation of Different Glycoform Clearance of a Biotherapeutic Mab in Human Serum
Chakrabarty Jayanta, Boehringer-Ingelheim, 2024
-
Glyco-Analysis of a Glycoengineered VHH-Radioligand Therapy Designed for Improved Biodistribution
Bush David, Novartis, 2024
-
Characterising Viral Vectors for Gene Therapy using Mass Spectrometry on Different Levels
Bones Jonathan, NIBRT, 2024
-
Proteoform Specific Microheterogeneity Assessment of Biopharmaceuticals Using a Modified Orbitrap Tribrid Mass Spectrometer
Beaumal Corentin, NIBRT, 2024
-
Advancements in Subzero Temperature Chromatography for HDX-MS
Speaker Presentation Anderson Kyle, NIST, 2024
-
Timing and Frequency of Forced Degradation and Variant Characterization Studies
Roundtables Session 1 – Table 8 Notes: Mass Spec 2024
-
New Mass Spec Methods to Tackle New Biotherapeutic Challenges
Roundtables Session 1 – Table 1 Notes: Mass Spec 2024
-
Multi-Attribute Method (MAM) in Development vs. MAM in QC
Roundtables Session 1 – Table 3 Notes: Mass Spec 2024
-
MS of RNA and Oligonucleotides: Characterization and Quantitation of PQAs
Roundtables Session 1 – Table 7 Notes: Mass Spec 2024
-
Methodologies to Assess/Predict Formulation and In Vivo Stability of Novel Modalities
Roundtables Session 1 – Table 6 Notes: Mass Spec 2024
-
Mass Spec for Higher Order Structure in Biologics Development
Roundtables Session 1 – Table 5 Notes: Mass Spec 2024